An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge (Q39642585)

13 September 2017

An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge (English)

1 reference

13 September 2017

7

Mark G Lewis

1 reference

13 September 2017

14

David B Weiner

1 reference

13 September 2017

Natalie A Hutnick

1

1 reference

13 September 2017

Devin J F Myles

2

1 reference

13 September 2017

Lauren Hirao

3

1 reference

13 September 2017

Veronica L Scott

4

1 reference

13 September 2017

Bernadette Ferraro

5

1 reference

13 September 2017

Amir S Khan

6

1 reference

13 September 2017

Christopher J Miller

8

1 reference

13 September 2017

Andrew J Bett

9

1 reference

13 September 2017

Danilo Casimiro

10

1 reference

13 September 2017

Niranjan Y Sardesai

11

1 reference

13 September 2017

J Joseph Kim

12

1 reference

13 September 2017

John Shiver

13

1 reference

13 September 2017

language of work or name

English

0 references

publication date

8 March 2012

1 reference

13 September 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 September 2017

30

1 reference

13 September 2017

21

1 reference

13 September 2017

3202-3208

1 reference

Live attenuated AIDS viruses as vaccines: promise or peril?

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

7 January 2021

DNA drugs come of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

A statistically defined endpoint titer determination method for immunoassays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

HIV-associated immune activation: from bench to bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Depo-Provera does not alter disease progression in SIVmac-infected female Chinese rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.069

10.1016/J.VACCINE.2012.02.069

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference